cResponse™, a diagnostic tool that combines rapid genomic sequencing and an innovative functional test, to assist oncologists in prioritizing treatments for their patients
The cResponse™ solution
cResponse™ combines rapid genomic sequencing with a functional test, enabling prioritization of different therapeutic options for patients with metastatic cancer.
The cResponse™ advantage
It is well established that all tumors are different and will respond differently to anti- cancer drugs. Genomic sequencing identifies actionable genomic alterations and potential therapeutic options and the cResponse™ test evaluates them on patient tumor samples.
The tumor microenvironment (TME), plays a central role in drug response and in many cases is a major factor in the development of resistance for cancer drugs. The cResponse™ platform preserves the tissue’s 3D structure and maintains the TME (including vasculature and immune system), enabling assessment of tumor response to drugs in laboratory conditions and prioritization of drugs based on their potential effect.
The testing procedure
A fresh biopsy arrives at a regional cResponse™ Service Center. Part of the sample undergoes rapid genomic sequencing to identify tumor-specific genomic alterations that may be targeted by specific anti-cancer drugs. Added to those selected by the physician, they create a panel of therapies to be tested in the system. The biopsy is cut into thick sections and placed in a proprietary assay culture matrix which tests the cancer’s sensitivity to various drugs or novel drug combinations. cResponse’s proprietary evaluation system and response algorithm then prioritizes the options according to demonstrated drug efficacy, providing results, usually within two weeks.
A patient’s cResponse™ score
After evaluation in the cResponse™ system and proprietary algorithm, each drug is assigned a score of 0-100, with 100 reflecting a strong response of the tissue to this therapy and 0 reflecting no response. The highest scoring drugs represent the most efficacious treatment in our proprietary assay. The Response™ score chart and images of patient tissue are included in the report.
Pathological evaluation of the sections
Prior to analysis, the slides are stained with H&E and Ki67, and are then evaluated by our team of in-house pathologists.The response of the tissue sections to drug or drug combination is analyzed by several parameters: viability, quality and proliferation of the cancer cells on the slide. The values are computed to generate a final score, which represents the tissue response.
A list of the genes tested in our panel
286 amplicons covering hotspots of 57 actionable genes:
ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MPL, MSH6, NOTCH1, NMP1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53 (whole CDS coverage), TSC1, TSC2, VHL.
Upon conclusion of the test and analysis, we will provide a comprehensive report, summarizing the genomic information identified in our rapid 57-gene panel test, the different drugs we tested and the effect of each tested drug on the tumor sample as assessed in our platform.